Pre-CongressSymposium3(Dosimetry/RadiationProtection)
Saturday,October21,2017,09:00–12:00
SessionTitle
ClinicalIntroductionofNewRadiotherapeutics:ChallengesandOpportunities
Chairs
GlennFlux(London)
MarkKonijnenberg(Rotterdam)
Programme
09:00–09:15 GlennFlux(London)&MarkKonijnenberg(Rotterdam):Introduction
09:15–09:30 AshSoman(Sydney):Phosphorous-32Microparticles
09:30–09:45 FrankNijsen(Groningen):Holmium-166Microspheres
09:45–10:00 ThibaultMauxion(Nantes):Y-90GlassMicrospheres
10:00–10:15 JürgenGay(Berlin):AlphaTherapywithRadium-223andThorium-227
10:15–10:45 CoffeeBreak
10:45–11:00 Jostein Dahle (Oslo): Treatment of NHL with Lutetium-177 Labelled Anti-CD37
Antibodies
11:00–11:15 StefanoBuono(Saint-Genis-Pouilly):Lutetium-177PeptidesandAntibodies
11:15–11:30 MichaelTapner(Sydney)Y-90ResinMicrospheres
11:30–12:00 PanelDiscussion:OpportunitiesforCollaborations
EducationalObjectives
1. Tolearnofnewradiotherapeuticscurrentlyemerging.
2. Togainanunderstandingoftheissuesinvolvedinbringinganewradiotherapeuticintoclinical
practiceandmaintainitsregistration.
3. Tounderstandthedevelopmentofnewpatient-specificradiotherapeuticdrugs.
4. Torealizethevariousmethodsforoptimisingradiotherapeutictreatmentschedules.
Summary
An ever increasing number of commercial radiotherapeutics are entering the clinic, signalling a
dramaticchangefromthesmallnumberofwellestablishedproducts,someofwhichhavebeenused
forover60years.Thereareestimatedtobe10-20newproductsindevelopmentorinearlyphase
clinicaltrials,andthemarketispredictedtogrowsignificantlyintheforeseeablefuture.Thisexplosion
of activity brings unprecedented opportunities for nuclear medicine, but also a host of challenge
relatingtoregulations,variationsinproceduresandpracticethroughoutEurope.Largeinvestments
areinvolvedwithdataacquisitionforlicensingproductapprovalandclinicaloptimisationofanew
agent,ofteninanalreadycompetitivemarket.
Withaviewtopursuingthecommonaimofpromotingtheuseofradiotherapeuticsforthetreatment
of cancer this symposium will share the experiences of established and new radiopharmaceutical
companiesandwillconsiderhowthenuclearmedicinecommercial,clinicalandresearchcommunities
canbestcooperateforthebenefitofthepatient.